Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001564590-17-005547
Filing Date
2017-03-30
Accepted
2017-03-29 18:48:10
Documents
91
Period of Report
2016-12-31

Document Format Files

Seq Description Document Type Size
1 10-K orex-10k_20161231.htm 10-K 3951338
2 EX-23.1 orex-ex231_10.htm EX-23.1 4578
3 EX-31.1 orex-ex311_9.htm EX-31.1 12668
4 EX-31.2 orex-ex312_8.htm EX-31.2 12646
5 EX-32.1 orex-ex321_11.htm EX-32.1 9548
  Complete submission text file 0001564590-17-005547.txt   13656075

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT orex-20161231.xml EX-101.INS 2979183
7 XBRL TAXONOMY EXTENSION SCHEMA orex-20161231.xsd EX-101.SCH 84430
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE orex-20161231_cal.xml EX-101.CAL 92138
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE orex-20161231_def.xml EX-101.DEF 358284
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE orex-20161231_lab.xml EX-101.LAB 695422
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE orex-20161231_pre.xml EX-101.PRE 550602
Mailing Address 3344 N. TORREY PINES CT. SUITE 200 LA JOLLA CA 92037
Business Address 3344 N. TORREY PINES CT. SUITE 200 LA JOLLA CA 92037 (858) 875-8600
Orexigen Therapeutics, Inc. (Filer) CIK: 0001382911 (see all company filings)

EIN.: 651178822 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-33415 | Film No.: 17723324
SIC: 2834 Pharmaceutical Preparations